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Imran Ahmad,1 Annie-Claude Labbe,2 Miguel Chagnon,3 Lambert Busque,1 Sandra Cohen,1
Thomas Kiss,1 Silvy Lachance,1 Denis-Claude Roy,1 Guy Sauvageau,1 Jean Roy1Data from a numberof cohorts indicate that eosinophilia (Eo) could be associated with better outcomes follow-
ing allogeneic hematopoietic cell transplant (HCT). However, little is known about its significance and prognostic
value in chronic graft-versus-host disease (cGVHD) after nonmyeloablative (NMA) transplantation. Data were
collected from 170 patients who underwent HCTusing the same preparative regimen and GVHD prophylaxis.
Donors were 6/6HLA-matched siblings and stem cell sourcewas peripheral blood. An eosinophil count of$0.5
 109/L was defined as Eo. Patients were transplanted mainly for lymphoproliferative disorders. Median age and
follow-upwere 54 years and 58months, respectively. Incidents of grade II-IVacuteGVHD(aGVHD) and cGVHD
were8.2%and81.2%.Median time fromHCTtocGVHDdiagnosiswas 142days.Organs involvedwere:mouth in
80%of patients, skin in 75%, liver in 57%, eyes in 37%, gut in 14%, lungs in 5%, others in 5%. Eowas found in 44%of
patients at diagnosis of cGVHD (range: 0.5-4.4 109/L). Median time between first appearance of Eo and diag-
nosis of cGVHD was 4.5 days. We found no correlation between organ involvement and Eo but a lower preva-
lence of Eo in cGVHD associated with thrombocytopenia (P5.023). Nevertheless, we observed no association
among Eo and overall survival (OS), relapse incidence, or nonrelapse mortality (NRM) in the overall cohort, nor
in subsets of patients with multiple myeloma and follicular non-Hodgkin lymphoma. Although Eo is observed
frequently in cGVHD following NMA transplantation, we report no correlation beween Eo and outcome.
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remains the main cause of impaired quality of life,
morbidity, and mortality in survivors of this potentially
curative procedure [1]. Clinical presentation of cGVHD
is pleomorphic, and classification attempts have vari-
ously integrated presenting signs and symptoms [2,3].
The prognostic implication of these classifications has
been validated in several studies [4-6]. Besides strictly
clinical features, a number of biologic values are
also of high relevance, including thrombocytopenia,
which is reportedly an independent marker of adverse
prognosis in patients with cGVHD [7,8]. Another
blood count abnormality, eosinophilia (Eo), is often
present at diagnosis of cGVHD. It was indeed
mentioned in the first description of cGVHD in
a patient series 30 years ago; several subsequent
reports have emphasized its occurrence well before
clinical manifestations of cGVHD become apparent
[3]. Even though several teams have reported a favorable
impact after HCT regardless of the time of Eo1673
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presenting with cGVHDhas not been studied until very
recently. In a retrospective analysis of sibling donor
allogeneic HCT recipients in 2009, Kim et al. [12]
observed a strong advantage in outcome of patients
with late-onset Eo, notably less severe cGVHD, better
GVHD-specific survival, lower nonrelapse mortality
(NRM), and better overall survival (OS) [12].
An increasing number of reduced-intensity
conditioning (RIC) and nonmyeloablative (NMA) con-
ditioning regimens are currently being used for alloge-
neic HCT [13]. These regimens have the advantage of
lower early toxicity and decreased incidence of acute
GVHD (aGVHD); however, they may be associated
with higher rates of cGVHD [14]. In this study, we
sought to determine both the incidence and prognostic
relevance of Eo in a large, homogenous cohort of pa-
tients who underwent sibling NMA allogeneic HCT.METHODS
We retrospectively analyzed data obtained from
170 adult patients who underwent allogeneic NMA
HCT between January 1, 2001, and December 31,
2008, at Maisonneuve-Rosemont Hospital (Montreal,
Canada), a tertiary care hospital accredited by the
Foundation for Accreditation of Cellular Therapy
and affiliated with the University of Montreal. The in-
stitutional Research Ethics Committee approved data
collection, analysis, and publication.
Transplant Procedure, GVHD Prophylaxis,
and Treatment
All patients received a conditioning regimen con-
sisting of fludarabine 30 mg/m2 daily intravenously
(i.v.) and cyclophosphamide 300 mg/m2 i.v. daily for 5
days, followed by infusion of a minimum of 4  106
CD341 blood stem cells/kg of the recipient’s body
weight. No attempt was made to reduce CD341 graft
content. Oral tacrolimus 3 mg twice daily was started
on day (D) 28, adjusted to achieve trough blood levels
of 10-15 nmol/L, continued until D 150, and then ta-
pered completely by D 1100 or 1180 according to es-
timated risk of relapse.Mycophenolate mofetil 1000mg
twice daily was started on D 11 and discontinued on
D 150. No total body irradiation (TBI) was used [15].
Immunoglobulins and granulocyte-colony stimulating
factor (G-CSF) were not routinely administered after
transplantation. All patients were given 6/6 HLA
identical grafts from a related donor and followed by
the same HCT physicians until death or loss to
follow-up. This NMA conditioning regimen protocol
was designed for use in an outpatient clinic setting.
aGVHD and cGVHD were diagnosed and graded us-
ing established criteria [3,16]. All efforts were made to
obtain tissue biopsy to confirm GVHD diagnosis.Treatment of aGVHD consisted of i.v. methyl-
prednisolone (MP) 2 mg/kg/day and tacrolimus at
therapeutic levels. Mycophenolate mofetil (MMF)
was continued in patients already receiving it and was
initiated in grade III-IV aGVHD.Upper gastrointesti-
nal GVHDwas treated with MP 1 mg/kg/day and oral
beclomethasone 2 mg 4 times daily. After progression
or no response to 4 days of MP 2 mg/kg/day, aGVHD
was considered as steroid-refractory and second-line
treatment with daclizumab [17] or pentostatin [18]
was initiated. Patients with extensive cGVHD received
prednisone 1mg/kg/day; responsewas reassessed 6 to 8
weeks later, as almost all patients were diagnosed and
treated in an outpatient setting. In those without re-
sponse, tacrolimus (if not used at therapeutic levels)
was added. Refractory patients received either rituxi-
mab [19], pentostatin [20], or imatinib [21].
Prevention and Treatment of Infections
All transplant candidates seropositive for herpes
simplex virus were given oral acyclovir 200 mg three
times a day from D 21 until D 121 or resolution of
neutropenia. Cytomegalovirus (CMV) reactivation
was treated according to a preemptive strategy: candi-
dates seropositive for CMV or receiving a graft from
a CMV-seropositive donor were monitored weekly
by quantitative polymerase chain reaction (PCR; CO-
BAS AMPLICOR CMV MONITOR Test, Roche
Molecular Diagnostics, Laval, Quebec) testing from
D 114 until D 1100. Patients with a positive CMV
PCR were promptly treated with i.v. ganciclovir or
oral valganciclovir for a minimum of 4 weeks of total
antiviral treatment [22].
Definitions
aGVHD was defined as symptoms appearing be-
fore D 1100 posttransplantation. Diagnosis and grad-
ing of aGVHD were made according to Glucksberg
criteria [16]. Seattle criteria were used for diagnosis
and staging of cGVHD [3]. cGVHD was defined as
typical symptoms/signs appearing before or after
D 1100; patients with late-onset aGVHD were in-
cluded if they developed signs of cGVHD (overlap syn-
drome). Patients presenting with late-onset aGVHD
only were excluded from this study. Eo was defined as
an absolute eosinophil count of $0.5  109/L and an-
alyzed at the time of cGVHD diagnosis. Every effort
was made to exclude other potential causes of Eo
such as allergy or parasitic infection. Day of occurrence
of Eo before diagnosis of cGVHD was recorded in or-
der to assess median time before clinical symptoms or
signs. To compute sensitivity and specificity values of
Eo for diagnosis of cGVHD, Eo occurring at any
time in patients without cGVHDand cGVHDwithout
Eo were considered respectively as false-positive and
false-negative. Thrombocytopenia (\100  109/L)
Biol Blood Marrow Transplant 17:1673-1678, 2011 1675Eosinophilia in cGVHDwas used as a surrogatemarker for high-risk cGVHDas
previously published [7,8].
NRM was defined as death not related to disease
recurrence or progression, and overall survival (OS)
as time to death from any cause.
Statistics
Exact chi-square test and Wilcoxon test were used
to compare patients’ characteristics. Time-to-event
analyses were performed by the Kaplan-Meier (KM)
method, and a log-rank test was used for comparison
between OS functions. Cumulative incidence curves
were derived using competing risks when appropriate
(death for cGVHD and relapse, and relapse for
NRM) and compared using the Gray test. Cox propor-
tional hazards model was used to confirm the impact ofTable 1. Characteristics of patients with cGVHD (N5138)
All Patients with cGVHD
N5138
Gender
Male 83
Female 55
Age, median 54
<45 16
45-54 60
55-64 59
$65 3
Disease
MM 75
Follicular NHL 29
Other NHL* 16
CLL 9
Other† 9
Sex mismatch
F–> M 42
CMV serostatus (donor/recipient)
+/+ 24
2/+ 31
+/2 30
2/2 53
Prior acute GVHD 18
Grades II-IV 9
Grades III-IV 2
Overlap GVHD 19
Days from HCT to cGVHD, median 142
Thrombocytopenia 11
CD34+/kg in graft, median 9.5
Organ involvement with cGVHD
Mouth 110
Skin 103
Liver 78
Eyes 51
Gut 19
Lung 7
Joints/fascia 6
Vagina 2
Mucocutaneous only 11
Mucocutaneous + ocular 18
Mucocutaneous + ocular + liver 66
Eosinophilia defined as absolute peripheral blood eosinophils $ 0.5 x 109 /L.
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-
GI, gastrointestinal; HCT, hematopoietic cell transplantation; MM, multiple mye
*Other NHL include: diffuse large B-cell, marginal zone, transformed or mixe
†Other diseases include: acute myeloid leukemia, chronic myeloid leukemia, mconfounding risk factors for survival. Time of cGVHD
diagnosis was considered as a landmark for survival
analysis in patients with cGVHD. All analyses were
performed with Prism5 (GraphPad Software Inc.,
San Diego, CA) and SAS v.9.0 (SAS Institute Inc.,
Cary, NC) software packages, with a significance level
of .05.RESULTS
Population Characteristics
A total of 170 patients were included in the analysis.
Median patient age and follow-up were 54 years (range:
34-66) and 58 months (range: 12-109), respectively.
The most common indications for NMA HCT wereEosinophilia No Eosinophilia
PN561 % N577 %
38 62 45 58 0.727
23 38 32 42
55 53 0.155
6 10 10 13 0.468
23 38 37 48
30 49 29 38
2 3 1 1
36 59 39 51 0.079
9 15 20 26
7 11 9 12
2 3 7 9
7 11 2 3
18 30 24 31 1.000
8 13 16 21 0.661
14 23 17 22
15 25 15 19
24 39 29 38
7 11 11 14
2 3 7 9 0.298
0 0 2 3 0.503
6 10 13 17 0.345
140 148 0.276
1 2 10 13 0.023
9.3 9.65 0.720
51 84 59 77 0.395
50 82 53 69 0.114
37 61 41 53 0.394
23 38 28 36 1.000
6 10 13 17 0.321
3 5 4 5 1.000
3 5 3 4 1.000
2 3 0 0 0.194
4 7 7 9 0.755
7 11 11 14 0.800
31 51 35 45 0.608
host disease; CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus;
loma; NHL, non-Hodgkin lymphoma.
d, T-cell.
ixed neoplasms, myelodysplastic syndromes.
Figure 1. OS in patients with cGVHD according to presence (n5 61)
of Eo or not (n 5 77).
Figure 2. Relapse incidence in patients with cGVHD according to
presence (n 5 61) of Eo or not (n 5 77).
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tiple myeloma (MM) in 52%, follicular non-Hodgkin
lymphoma (NHL) in 23%, other NHLs in 11%, and
chronic lymphocytic leukemia in 2% of patients. Other
diseases included acute leukemias and myelodysplastic
syndromes. Groups with and without cGVHD were
well balanced for gender, age, sex mismatch, CMV
serostatus, and aGVHD.
GVHD and Eo
Acute GVHD was seen in 13.5% (95% confidence
interval [CI]: 8.8%-19.6%) of patients, with grade II-IV
in 8.2% (95% CI: 4.6%-13.4%) and grade III-IV in
only 1.8% (95%CI: 0.4%-5.0%). Chronic GVHD oc-
curred in 81.2% (95% CI: 74.5%-86.8%) of patients;
median time from NMA transplantation to diagnosis
of cGVHD was 142 days (range: 66-1042). An overlap
syndrome with both acute and chronic features was ob-
served in 11.2% (95% CI: 6.44%-15.92%) of patients;
no case of isolated late-onset aGVHD was detected.
Organs affected by cGVHD are shown in Table 1.
Only a minority (11%) of patients presented with
single organ involvement. Eo was present in 44.2%
(95% CI: 35.8%-52.9%) of patients at onset of
cGVHD; all patients but 14 (on steroids for treatment
of aGVHD) were off immunosuppressants when
cGVHD was first detected. Median time from first de-
tection of Eo and first clinical description of signs or
symptoms of cGVHD was 4.5 days, although exact de-
termination of this interval would have required daily
patient evaluation. There was no difference in organ
involvement distribution between groups with and
without Eo. Thrombocytopenia, a potential high-risk
feature, was present in only 11 patients (8%) with
cGVHD, of whom only 1 had associated Eo (9%); in
sharp contrast, Eo was observed in 47% of patients
without thrombocytopenia (P 5 .023). Eight of 32 pa-
tients (25%) who never developed cGVHD presented
with transient Eo, without evidence of allergy or
infection; median time of onset was D 1184.
After initiation of cGVHD therapy, the eosinophil
count returned promptly to normal (\0.5  109/L)
on the next visit in all but 6 (90%) patients, and even
#0.2  109/L in 87% of patients. Sensitivity and
specificity of Eo for diagnosis of clinically apparent
cGVHD is 44% (95% CI: 36%-53%) and 75%
(95% CI: 56%-88%), respectively. Positive and nega-
tive predictive values are 88% (95% CI: 78%-95%)
and 24% (95% CI: 16%-33%), respectively.
Difference in Survival among cGVHD Patients
with or without Eo
With a median follow-up of 58 months, survival
analyses in cGVHD patients with or without Eo
showed no difference in OS, relapse incidence,
and NRM (Figures 1-3). Time-dependent Coxproportional hazards analysis confirmed the absence
of impact of Eo on survival (hazard ratio [HR] 5
4.106, P 5 .1070). In addition, when controlled for
platelet count in a Cox regression model, Eo did
not impact survival (HR5 0.739, P5 .4569). In order
to assess outcome in strictly de novo cGVHD (ie, not
exposed to steroids), we also conducted survival
analyses in this subgroup, after exclusion of patients
with previous aGVHD. OS, NRM, and relapse
incidence were not different between patients with
or without Eo (data not shown). Finally, analyses in
subgroups of patients with MM and follicular NHL
yielded similar results (data not shown).DISCUSSION
We report a prevalence of Eo of 44% at onset of
cGVHD in a large homogenously treated cohort of
NMA 6/6 sibling HCT recipients, characterized by
very low NRM, low incidence of aGVHD, and high
incidence of cGVHD. Most of our 138 patients had
de novo cGVHD, without previous exposure to
Figure 3. Nonrelapse mortality in 138 patients with cGVHD according
to the presence (n 5 61) of Eo or not (n 5 77).
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cohort a unique opportunity to evaluate the role of
Eo in human cGVHD without interference of
aGVHD. Our results are consistent with previously
published data and similar to the observed incidence
of Eo in cGVHD after myeloablative transplantations
[3,7]. Because Eo was absent in more than one-half
of patients at diagnosis of cGVHD, its negative
predictive value is very low, whereas its positive
predictive value is high at 88%. Similarly, Kim et al.
[12] have shown that late-onset (.100 days posttrans-
plantation) Eo is associated with cGVHD in 86% of
patients, which also reflects a high positive predictive
value for cGVHD. We can therefore assume that Eo
occurring after D 1100 is a marker of cGVHD until
proven otherwise, and may reflect a subclinical im-
mune reaction when other causes are excluded.
The lower prevalence of Eo among cGVHD
patients with thrombocytopenia in our cohort is also
in keeping with recently published results by Kim
et al. [12], where Eo was more frequently observed in
low-risk cGVHD. Kim et al. [12] have hypothesized
that Eo is a surrogate for Th1/Th2 imbalance in favor
of Th2-type and B cell-mediated alloreactivity, which,
in turn, could result in mainly mucocutaneous forms of
cGVHD, thus less severe with better long-term out-
come. However, this remains to be defined prospec-
tively by immunologic studies correlating cytokine
secretion with clinical manifestations and outcome.
Of note, the prognostic value of thrombocytopenia
in cGVHD following myeloablative HCT is well
known, but it has not been formally validated in
NMA transplantation, which was not the objective of
the present study.
Although Eo is not included in the NIH cGVHD
staging system, monitoring eosinophil numbers was
proposed tomeasure therapeutic response in cGVHD.
After initiation of systemic steroids in patients with
cGVHD, we observed a rapid fall in the eosinophil
counts to undetectable levels in almost all patients
within only a few days, independent of clinicalresponse of cGVHD manifestations. This reflects the
sharp effect of glucocorticoids on eosinophil survival,
and, unfortunately, does not allow us to predict thera-
peutic response.
Surprisingly, in our study, Eo was not predomi-
nantly associated with mucocutaneous or any other
organ-specific form of cGVHD and did not seem to
have an impact on long-term clinical outcomes. Our
results are strikingly different than those published
by Kim et al. [12], who reported that late-onset Eo
was not only associated with less severe cGVHD, but
also with higher GVHD-specific survival, lower
NRM, and better OS. Additionally, methodologic in-
sensitivity associated with a retrospective approach
may have led to lower reported incidents of specific or-
gan involvement (eg, lungs) in our study compared
with other data.
There are major differences between Kim’s cohort
and ours, which may translate into different results.
First, all of our patients underwent NMA allogeneic
HCT according to the same protocol, whereas Kim
et al. [12] included mainly myeloablative (68%) trans-
plant recipients. Second, the early mortality and the
incidence of aGVHD (83% vs 14%) are much higher
than in our cohort. Exposure to glucocorticoids for
treatment of aGVHD, even at low doses, might
impede development of Eo. In addition, tapering of
immunosuppressive drugs was initiated at 3 months
posttransplantation in their cohort, whereas most of
our patients (.90%) had complete withdrawal by
D 1100, which might have contributed to a higher
incidence of cGVHD. Furthermore, Kim et al.’s [12]
cohort is composed of acute leukemias and myelodys-
plastic/myeloproliferative neoplasms, whereas our
population mainly includes lymphoproliferative disor-
ders. The latter are commonly associated with immune
dysregulation, which, in turn, may have influenced Eo
occurrence. Finally, other factors seldom measured in
retrospective studies, such as total exposure to immu-
nosuppression over time, could play a role through
different patterns of infectious complications.
In our study, we chose to focus on the role of Eo in
patients presenting with cGVHD, whereas Kim et al.
[12] also analyzed the impact of Eo at any time post-
transplantation regardless of presence/absence of
cGVHD. It is noteworthy to mention that survival
analysis according to a variable (ie, Eo) occurring at
a random time point after HCT cannot be conducted
by considering transplantation date as a landmark. For
that reason, we chose to compute outcomes in our
study based only on cGVHD presentation, which is
when comparison groups are well defined.
Our results are consistent with previous attempts
to define predictive factors for outcome in patients
with cGVHD, in which Eo did not discriminate be-
tween prognostic groups [6-8]. Grading and response
criteria for cGVHD were not standardized until the
1678 Biol Blood Marrow Transplant 17:1673-1678, 2011I. Ahmad et al.proposal from the NIH Consensus Development
Project on Criteria for Clinical Trials in cGVHD
[2]. We believe that applying these criteria retrospec-
tively to patients not clinically evaluated accordingly
would be incorrect, given that most were transplanted
before 2006. Therefore, the outcomes we chose to
evaluate for response to cGVHD therapy were NRM
and survival. This may be considered as a limitation
of this study. Only prospective studies on Eo in
cGVHD with emphasis on strict definitions and grad-
ing will provide definitive conclusions regarding its
prognostic value.
Based on recently published new criteria for the di-
agnosis of cGVHD, it has become commonplace to
start systemic treatment in moderate or severe cases
based on organ presentation [2]. Eo, although men-
tioned in accompanying features, is not taken into ac-
count in the grading system. Of importance, one could
hypothesize that treatment initiation at onset of Eo
might prevent or lessen significant organ damage.
However, this will need to be verified in prospective
trials. Although Eo is useful as a predictive biomarker
for diagnosis of cGVHD because of its high positive
predictive value, it does not carry any prognostic rele-
vance after NMA transplantation. For the time being,
we believe it remains premature to base prognostic and
therapeutic conclusions on the occurrence of Eo after
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